In a report released yesterday, Lorenzo Biasio from Credit Suisse maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target of $104.00. The company's shares closed last Wednesday at $87.62. According to TipRanks.com, Biasio is a 4-star analyst with an average return of 7.0% and a 61.3% success rate. Biasio covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Coherus Biosciences, and Intuitive Surgical. Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $100.00, a 14.6% upside from current levels.
https://www.tipranks.com/news/blurbs/credit-suisse-sticks-to-their-buy-rating-for-merck-company-mrk-2?utm_source=advfn.com&utm_medium=referral
Merck (NYSE:MRK)
Historical Stock Chart
Von Sep 2022 bis Okt 2022 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
Von Okt 2021 bis Okt 2022 Click Here for more Merck Charts.